Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

In its weekly update today, the US Centers for Disease Control and Prevention (CDC) reported 40 more measles cases today, ...

Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

Cambodia’s health ministry today reported a seventh human H5N1 avian flu case for the month of June, a 36-year-old woman from ...

Recent mosquito-borne illness patterns in Europe reflect the growing geographic spread and public health impact of the ...

The New Mexico Department of Health (NMDH) today reported eight more measles cases, all from Luna County, where officials ...

USAID, the world's largest funding agency for humanitarian and development, is estimated to have helped avert more than 91 ...

Livestock manure around the globe is packed with antibiotic resistance genes (ARGs) that could threaten human health, ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...